{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:26Z","timestamp":1793831306654,"version":"4.6.1"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jconrel.2023.11.012","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T21:36:41Z","timestamp":1700775401000},"page":"236-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies"],"prefix":"10.1016","volume":"365","author":[{"given":"Hamza","family":"Boucetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.11.012_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome","volume":"115","author":"Lai","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pcad.2012.07.002","article-title":"WHO Group 1 pulmonary arterial hypertension: current and investigative therapies","volume":"55","author":"Ventetuolo","year":"2012","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"2022","key":"10.1016\/j.jconrel.2023.11.012_bb0015","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0020","first-page":"306","article-title":"A global view of pulmonary hypertension, lancet","volume":"4","author":"Hoeper","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107576","article-title":"Pulmonary arterial hypertension specific therapy: the old and the new","volume":"214","author":"Zolty","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0035","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02334-2021","article-title":"The physiological basis of pulmonary arterial hypertension","volume":"59","author":"Naeije","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020941494","article-title":"Repurposing of medications for pulmonary arterial hypertension","volume":"10","author":"Toshner","year":"2020","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1183\/09059180.00007814","article-title":"The changing landscape of pulmonary arterial hypertension and implications for patient care","volume":"23","author":"Hoeper","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0050","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","article-title":"Lipid carriers for mRNA delivery","volume":"13","author":"Wanting Zhang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2019.12.001","article-title":"Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases","volume":"165\u2013166","author":"He","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0065","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0070","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0075","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41569-021-00517-4","article-title":"The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy","volume":"18","author":"Ricard","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.vph.2008.06.003","article-title":"Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension","volume":"49","author":"Humbert","year":"2008","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0095","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1183\/09031936.00193014","article-title":"Leptin signalling system as a target for pulmonary arterial hypertension therapy","volume":"45","author":"Huertas","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1164\/rccm.201402-0322OC","article-title":"Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor\/CD74 complex","volume":"192","author":"Le Hiress","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","author":"Tamura","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/CIRCULATIONAHA.113.007469","article-title":"Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension","volume":"129","author":"Ricard","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5040045","article-title":"Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases","volume":"5","author":"Piera-Velazquez","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0120","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cellsig.2016.06.022","article-title":"The role of PDGF-B\/TGF-beta1\/neprilysin network in regulating endothelial-to-mesenchymal transition in pulmonary artery remodeling","volume":"28","author":"Song","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14728222.2017.1275567","article-title":"Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations","volume":"21","author":"Guignabert","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0130","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/HYPERTENSIONAHA.112.198887","article-title":"Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor","volume":"60","author":"Liu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0135","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1172\/JCI137558","article-title":"Hypoxia-inducible factor signaling in pulmonary hypertension","volume":"130","author":"Pullamsetti","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-319-63245-2_14","article-title":"Metabolic reprogramming and redox signaling in pulmonary hypertension","volume":"967","author":"Plecita-Hlavata","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajpath.2011.03.040","article-title":"Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment","volume":"179","author":"Jonigk","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0150","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1084\/jem.20090389","article-title":"The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice","volume":"206","author":"Kugathasan","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0155","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","article-title":"A selective transforming growth factor-beta ligand trap attenuates pulmonary hypertension","volume":"194","author":"Yung","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0160","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1161\/01.CIR.0000018622.84402.FF","article-title":"Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell","volume":"105","author":"Arita","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0165","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar3315","volume":"13","author":"Overbeek","year":"2011","journal-title":"Arthri. Res. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0170","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1378\/chest.126.4.1255","article-title":"Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension","volume":"126","author":"Benisty","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201410-1851OC","article-title":"Role of nerve growth factor in development and persistence of experimental pulmonary hypertension","volume":"192","author":"Freund-Michel","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061338","article-title":"Progenitor\/stem cells in vascular remodeling during pulmonary arterial hypertension","volume":"10","author":"Dierick","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0185","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/ATVBAHA.119.313715","article-title":"Lineage tracing reveals the dynamic contribution of Pericytes to the blood vessel remodeling in pulmonary hypertension","volume":"40","author":"Bordenave","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.rmr.2019.03.003","article-title":"New insights in the pathogenesis of pulmonary arterial hypertension","volume":"36","author":"Bordenave","year":"2019","journal-title":"Rev. Mal. Respir."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0195","first-page":"L370","article-title":"BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways","volume":"288","author":"Jeffery","year":"2005","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112338","article-title":"Perivascular inflammation in pulmonary arterial hypertension","volume":"9","author":"Hu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1465-9921-10-95","article-title":"Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation","volume":"10","author":"Sakao","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12944-015-0174-3","article-title":"TGF-beta1\/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts","volume":"15","author":"Zhang","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0215","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1183\/09031936.00039811","article-title":"Circulating fibrocytes and pulmonary arterial hypertension","volume":"39","author":"Gambaryan","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0220","doi-asserted-by":"crossref","first-page":"H1332","DOI":"10.1152\/ajpheart.00198.2018","article-title":"MMP-2: is too low as bad as too high in the cardiovascular system?","volume":"315","author":"Hardy","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.jhh.1001814","article-title":"Large artery stiffness and inflammation","volume":"19","author":"McEniery","year":"2005","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","article-title":"Management of Pulmonary Arterial Hypertension","volume":"15","author":"Mayeux","year":"2021","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0235","first-page":"62","article-title":"The role of endothelin-1 in pulmonary arterial hypertension","volume":"2014","author":"Chester","year":"2014","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0240","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2019.02.067","article-title":"Immunotherapy of Endothelin-1 receptor type a for pulmonary arterial hypertension","volume":"73","author":"Dai","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0245","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Galie","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1753465817696040","article-title":"Ambrisentan: a review of its use in pulmonary arterial hypertension","volume":"11","author":"Rivera-Lebron","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fca-2020-0012","article-title":"Macitentan in the treatment of pulmonary arterial hypertension","volume":"17","author":"Zebadua","year":"2021","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0260","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/crj.12774","article-title":"Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a systemic review and meta-analysis","volume":"12","author":"Chen","year":"2018","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.767002","article-title":"Therapy for pulmonary arterial hypertension: glance on nitric oxide pathway","volume":"12","author":"Tettey","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0270","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/XEB.0000000000000198","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"18","author":"Pich","year":"2020","journal-title":"Int. J. Evid. Based Healthc."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0275","first-page":"573","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial, lancet","volume":"9","author":"Hoeper","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0280","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1097\/MJT.0000000000000766","article-title":"Sildenafil for pulmonary arterial hypertension","volume":"26","author":"Bhogal","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0285","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/11204580-000000000-00000","article-title":"Tadalafil: in pulmonary arterial hypertension","volume":"70","author":"Croxtall","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0295","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2017.03.003","article-title":"Targeting the prostacyclin pathway: beyond pulmonary arterial hypertension","volume":"38","author":"Pluchart","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0300","article-title":"Use of Epoprostenol in the treatment of pulmonary arterial hypertension","volume":"13","author":"Mohammadi","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.13305","article-title":"The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension","volume":"126","author":"Lindegaard Pedersen","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0310","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201001-0011OC","article-title":"Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension","volume":"182","author":"Falcetti","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003495-200262010-00005","article-title":"Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension","volume":"62","author":"Melian","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0320","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0325","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029024","article-title":"Revised definition of pulmonary hypertension and approach to management: a clinical primer","volume":"12","author":"Maron","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension","volume":"21","author":"Bisserier","year":"2020","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0335","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/17425247.2015.961418","article-title":"Endothelial nanomedicine for the treatment of pulmonary disease","volume":"12","author":"Brenner","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0340","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the Meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"2016","key":"10.1016\/j.jconrel.2023.11.012_bb0345","first-page":"67","volume":"37","author":"Galie","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121792","article-title":"Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial hypertension","volume":"621","author":"Dhoble","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0355","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2146\/ajhp060357","article-title":"Sitaxsentan in the management of pulmonary arterial hypertension","volume":"64","author":"Benedict","year":"2007","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.niox.2019.12.001","article-title":"Inhaled nitric oxide use in neonates: balancing what is evidence-based and what is physiologically sound","volume":"95","author":"Sherlock","year":"2020","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0365","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"vol. 9","author":"Graf","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCRESAHA.118.314270","article-title":"In search of the second hit in pulmonary arterial hypertension","volume":"124","author":"Yang","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0375","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.healun.2008.02.009","article-title":"Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension","volume":"27","author":"Rosenzweig","year":"2008","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0380","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0385","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0390","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/CIRCULATIONAHA.113.004555","article-title":"Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay","volume":"129","author":"Huertas","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0395","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00314-2020","article-title":"IL-6 in pulmonary hypertension: why novel is not always best","volume":"55","author":"Toshner","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0400","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1172\/JCI120415","article-title":"Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension","volume":"128","author":"Pullamsetti","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0405","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0410","article-title":"Glycoprotein 130 inhibitor ameliorates Monocrotaline-induced pulmonary hypertension in rats","volume":"32","author":"Huang","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0415","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bph.14826","article-title":"The role of chemokines and chemokine receptors in pulmonary arterial hypertension","volume":"178","author":"Mamazhakypov","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0420","first-page":"L50","article-title":"Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation","volume":"301","author":"Larsen","year":"2011","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0425","first-page":"275","article-title":"Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension","volume":"12","author":"Marasini","year":"2005","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0430","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","article-title":"Chemokine RANTES in severe pulmonary arterial hypertension","volume":"165","author":"Dorfmuller","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0435","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physiolgenomics.00261.2007","article-title":"Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats","volume":"34","author":"Zagorski","year":"2008","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0440","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCULATIONAHA.114.010757","article-title":"CCR5 as a treatment target in pulmonary arterial hypertension","volume":"130","author":"Amsellem","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0445","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0033-1356494","article-title":"Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?","volume":"34","author":"Godinas","year":"2013","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0450","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/978-3-642-38664-0_16","article-title":"Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension","volume":"218","author":"Berghausen","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0455","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1086\/677359","article-title":"Imatinib in pulmonary arterial hypertension: c-kit inhibition","volume":"4","author":"Farha","year":"2014","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0460","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2017.03.009","article-title":"Sorafenib as a potential strategy for refractory pulmonary arterial hypertension","volume":"44","author":"Kimura","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0465","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"Abe","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0470","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.14608","article-title":"Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib","volume":"177","author":"Minami","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0475","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pharmthera.2013.02.002","article-title":"Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension","volume":"138","author":"Thomas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0480","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1161\/ATVBAHA.116.308929","article-title":"Serotonin signaling through the 5-HT(1B) receptor and NADPH oxidase 1 in pulmonary arterial hypertension","volume":"37","author":"Hood","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0485","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.RES.0000215809.47923.fd","article-title":"Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice","volume":"98","author":"Long","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0490","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000250322","article-title":"Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease","volume":"79","author":"Ulrich","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12088","article-title":"A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)","volume":"12","author":"Lazarus","year":"2022","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0500","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1620\/tjem.211.309","article-title":"Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors","volume":"211","author":"Fukumoto","year":"2007","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0505","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1879-3111","article-title":"The therapeutic role of rho kinase inhibitor, Fasudil, on pulmonary hypertension; a systematic review and Meta-analysis","volume":"73","author":"Abedi","year":"2023","journal-title":"Drug Res. (Stuttg)"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0510","article-title":"Rho kinase and Na(+) \/H(+) exchanger mediate endothelin-1-induced pulmonary arterial smooth muscle cell proliferation and migration","volume":"6","author":"Huetsch","year":"2018","journal-title":"Phys. Rep."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0515","first-page":"4988","article-title":"TGF-beta1 promotes pulmonary arterial hypertension in rats via activating RhoA\/ROCK signaling pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0520","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00408-010-9233-8","article-title":"Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis","volume":"188","author":"Huang","year":"2010","journal-title":"Lung"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0525","first-page":"L667","article-title":"Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene","volume":"301","author":"Yasuda","year":"2011","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0530","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/DDDT.S297500","article-title":"Fasudil Dichloroacetate alleviates SU5416\/hypoxia-induced pulmonary arterial hypertension by ameliorating dysfunction of pulmonary arterial smooth muscle cells","volume":"15","author":"Liu","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0535","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.bmcl.2019.05.006","article-title":"Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats","volume":"29","author":"Qi","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0540","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1183\/09031936.00130209","article-title":"Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil","volume":"36","author":"Mouchaers","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/biom12101341","article-title":"Potassium channels as therapeutic targets in pulmonary arterial hypertension","volume":"12","author":"Redel-Traub","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00246-016-1491-7","article-title":"The action of smooth muscle cell potassium channels in the pathology of pulmonary arterial hypertension","volume":"38","author":"Hayabuchi","year":"2017","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0555","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1113\/JP276054","article-title":"miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries","volume":"597","author":"Mondejar-Parreno","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0560","first-page":"6973636","article-title":"Combination of Dichloroacetate and atorvastatin regulates excessive proliferation and oxidative stress in pulmonary arterial hypertension development via p38 signaling","volume":"2020","author":"Li","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0565","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.185.7.786","article-title":"Vasoactive intestinal peptide in pulmonary arterial hypertension","volume":"185","author":"Said","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0570","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.peptides.2010.04.024","article-title":"Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation","volume":"31","author":"St Hilaire","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020341","article-title":"Mitochondrial metabolism, redox, and calcium homeostasis in pulmonary arterial hypertension","volume":"10","author":"Liang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0580","doi-asserted-by":"crossref","first-page":"44ra58","DOI":"10.1126\/scitranslmed.3001327","article-title":"Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension","volume":"2","author":"Sutendra","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0585","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-physiol-031620-123956","article-title":"Metabolism in pulmonary hypertension","volume":"83","author":"Xu","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0590","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3389\/fphys.2018.00890","article-title":"Nanotherapeutics for treatment of pulmonary arterial hypertension","volume":"9","author":"Segura-Ibarra","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0595","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jconrel.2021.12.006","article-title":"Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension","volume":"341","author":"Teng","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27113490","article-title":"An update on advancements and challenges in inhalational drug delivery for pulmonary arterial hypertension","volume":"27","author":"Agnihotri","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0605","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.addr.2013.07.020","article-title":"Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases","volume":"65","author":"Andrade","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0610","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apsb.2021.08.009","article-title":"Pulmonary delivery of siRNA against acute lung injury\/acute respiratory distress syndrome","volume":"12","author":"Zoulikha","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0615","first-page":"817","article-title":"Liposomes and liposome-like nanoparticles: from anti-fungal infection to the COVID-19 pandemic treatment, Asian","volume":"17","author":"He","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0620","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1016\/j.cclet.2022.01.083","article-title":"Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy","volume":"33","author":"Qingqing Xiao","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0625","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","article-title":"Biological drug and drug delivery-mediated immunotherapy","volume":"11","author":"Xiao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0630","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1021\/acs.molpharmaceut.7b01003","article-title":"Fasudil and DETA NONOate, loaded in a peptide-modified liposomal carrier, slow PAH progression upon pulmonary delivery","volume":"15","author":"Rashid","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0635","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/HYPERTENSIONAHA.118.11932","article-title":"Targeted delivery of sildenafil for inhibiting pulmonary vascular remodeling","volume":"73","author":"Li","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0640","article-title":"Ethosomes: a novel drug carrier","volume":"82","author":"Chauhan","year":"2022","journal-title":"Ann. Med. Surg. (Lond.)"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0645","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.2147\/IJN.S261764","article-title":"Ethosome-derived Invasomes as a potential transdermal delivery system for Vardenafil hydrochloride: development, optimization and application of physiologically based pharmacokinetic modeling in adults and geriatrics","volume":"15","author":"Ammar","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118817","article-title":"Transferosomes as nanocarriers for drugs across the skin: quality by design from lab to industrial scale","volume":"573","author":"Fernandez-Garcia","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08982104.2014.950276","article-title":"Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett-Burman design and characterization","volume":"25","author":"Ahmed","year":"2015","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0660","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/DDDT.S103122","article-title":"Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation","volume":"10","author":"Badr-Eldin","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0665","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jconrel.2020.12.053","article-title":"Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation","volume":"330","author":"Kim","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0670","doi-asserted-by":"crossref","first-page":"1090909","DOI":"10.3389\/fcvm.2023.1090909","article-title":"Emerging role of exosomes in vascular diseases","volume":"10","author":"Ren","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0675","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1161\/CIRCULATIONAHA.112.114173","article-title":"Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension","volume":"126","author":"Lee","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0680","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1165\/rcmb.2019-0154OC","article-title":"Mesenchymal stem cell extracellular vesicles reverse Sugen\/hypoxia pulmonary hypertension in rats","volume":"62","author":"Klinger","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0685","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41467-020-14966-x","article-title":"Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension","volume":"11","author":"Sindi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0690","doi-asserted-by":"crossref","first-page":"eaaw6870","DOI":"10.1126\/sciadv.aaw6870","article-title":"Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy","volume":"5","author":"Han","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0695","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s11095-013-1261-7","article-title":"Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization","volume":"31","author":"Gupta","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0700","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ejpb.2014.10.012","article-title":"Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats","volume":"88","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0705","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/jpet.118.247643","article-title":"Cerivastatin Nanoliposome as a potential disease modifying approach for the treatment of pulmonary arterial hypertension","volume":"366","author":"Lee","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0710","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1021\/acs.molpharmaceut.9b00208","article-title":"CAR, a homing peptide, prolongs pulmonary preferential vasodilation by increasing pulmonary retention and reducing systemic absorption of liposomal Fasudil","volume":"16","author":"Keshavarz","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0715","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/IJN.S294626","article-title":"In vivo pharmacokinetics and in vitro release of Imatinib Mesylate-loaded liposomes for pulmonary delivery","volume":"16","author":"Xu","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0720","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1208\/s12249-022-02312-x","article-title":"SIRT 1 activator loaded inhaled antiangiogenic liposomal formulation development for pulmonary hypertension","volume":"23","author":"Dhoble","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0730","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.2174\/1381612825666190903155321","article-title":"Solid lipid nanoparticles: a promising nanomaterial in drug delivery","volume":"25","author":"Rajpoot","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0735","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jconrel.2021.05.032","article-title":"Solid lipid nanoparticles for hydrophilic drugs","volume":"335","author":"Mirchandani","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0740","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1872211311666171129115441","article-title":"Enhanced both in vitro and in vivo kinetics by SLNs induced transdermal system of furosemide: a novel approach","volume":"11","author":"Mannam","year":"2017","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0745","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fphar.2020.00083","article-title":"Formulation and characterization of solid lipid nanoparticles loading RF22-c, a potent and selective 5-LO inhibitor, in a Monocrotaline-induced model of pulmonary hypertension","volume":"11","author":"Liparulo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0750","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10717544.2020.1760962","article-title":"DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment","volume":"27","author":"Li","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121181","article-title":"Oral delivery of ambrisentan-loaded lipid-core nanocapsules as a novel approach for the treatment of pulmonary arterial hypertension","volume":"610","author":"Zancan","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0760","first-page":"1241","article-title":"Exploring the role of self-nanoemulsifying systems in drug delivery: challenges, issues, applications and recent advances","volume":"20","author":"Verma","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0765","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s13346-022-01247-x","article-title":"Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics","volume":"13","author":"Jain","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106159","volume":"174","author":"Usta","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0775","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0780","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejpb.2007.03.022","article-title":"Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs","volume":"66","author":"Chiappetta","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0785","series-title":"Smart Materials for Drug Delivery","first-page":"0","article-title":"Temperature- and pH-sensitive polymeric micelles for drug encapsulation, release and targeting","author":"Sosnik","year":"2013"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0790","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.biotechadv.2015.01.003","article-title":"Polymeric micelles in mucosal drug delivery: challenges towards clinical translation","volume":"33","author":"Sosnik","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0795","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/jps.24193","article-title":"Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension","volume":"103","author":"Gupta","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0800","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejpb.2014.10.010","article-title":"Pulmonary delivered polymeric micelles--pharmacokinetic evaluation and biodistribution studies","volume":"88","author":"Hu","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0805","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijpharm.2017.03.069","article-title":"Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension","volume":"524","author":"Segura-Ibarra","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zielinska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0815","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/10717544.2016.1239661","article-title":"Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption","volume":"24","author":"Hanna","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0820","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1038\/s41598-021-86781-3","article-title":"Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension","volume":"11","author":"Kanaya","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0825","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100302","article-title":"Intravenous delivery of lung-targeted nanofibers for pulmonary hypertension in mice","volume":"10","author":"Marulanda","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111878","article-title":"Hyaluronic acid hydrogels for controlled pulmonary drug delivery-a particle engineering approach","volume":"13","author":"Nikjoo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/ma14051095","article-title":"A review on the design and hydration properties of natural polymer-based hydrogels","volume":"14","author":"Karoyo","year":"2021","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0840","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12265-016-9684-2","article-title":"A new NO-releasing Nanoformulation for the treatment of pulmonary arterial hypertension","volume":"9","author":"Mohamed","year":"2016","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0845","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1536\/ihj.14-338","article-title":"Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension","volume":"56","author":"Akagi","year":"2015","journal-title":"Int. Heart J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0850","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2014.10.029","article-title":"Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension","volume":"197","author":"Ishihara","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0855","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1536\/ihj.17-683","article-title":"Nanoparticle-mediated targeting of Pitavastatin to small pulmonary arteries and leukocytes by intravenous administration attenuates the progression of Monocrotaline-induced established pulmonary arterial hypertension in rats","volume":"59","author":"Ichimura","year":"2018","journal-title":"Int. Heart J."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0860","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2018.04.049","article-title":"Repurposing rosiglitazone, a PPAR-gamma agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH","volume":"280","author":"Rashid","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2018.09.001","article-title":"Editorial: drug nanoparticles and Nano-Cocrystals: from production and characterization to clinical translation","volume":"131","author":"Sosnik","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0870","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1016\/j.cclet.2021.03.085","article-title":"Cocrystallization-like strategy for the codelivery of hydrophobic and hydrophilic drugs in a single carrier material formulation","volume":"32","author":"Yi Li","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.04.051","article-title":"Metal phenolic network-stabilized nanocrystals of andrographolide to alleviate macrophage-mediated inflammation in-vitro","volume":"34","author":"Magar","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0880","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.apsb.2021.03.014","article-title":"Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response","volume":"11","author":"Du","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0885","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0890","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2019.02.045","article-title":"Drug nanocrystals: fabrication methods and promising therapeutic applications","volume":"562","author":"Mohammad","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0895","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12249-022-02220-0","article-title":"A nanocrystal platform based on metal-phenolic network wrapping for drug Solubilization","volume":"23","author":"Huang","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0900","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2018.07.012","article-title":"Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals","volume":"131","author":"Sverdlov Arzi","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0905","first-page":"1335","article-title":"Enhanced dissolution rate of Tadalafil nanoparticles prepared by Sonoprecipitation technique: optimization and physicochemical investigation","volume":"16","author":"Teymouri Rad","year":"2017","journal-title":"Iran J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0910","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejps.2019.04.001","article-title":"Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment","volume":"133","author":"Teymouri Rad","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0915","first-page":"2369","article-title":"Alleviating experimental pulmonary hypertension via co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries","volume":"13","author":"Bingbing Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050895","article-title":"Dry powder formulation of simvastatin nanoparticles for potential application in pulmonary arterial hypertension","volume":"14","author":"Zendehdel Baher","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0925","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1166\/jbn.2017.2326","article-title":"Curcumin acetate nanocrystals for sustained pulmonary delivery: preparation, characterization and in vivo evaluation","volume":"13","author":"Hu","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0930","doi-asserted-by":"crossref","first-page":"9951","DOI":"10.1016\/j.biomaterials.2014.08.037","article-title":"Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension","volume":"35","author":"Kolli","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0935","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2019.11.030","article-title":"Feedback-controlled photolytic gas phase nitric oxide delivery from S-nitrosothiol-doped silicone rubber films","volume":"318","author":"Lautner","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0940","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.18632\/aging.202215","article-title":"Amorphous nano-selenium quantum dots prevent pulmonary arterial hypertension through recoupling endothelial nitric oxide synthase","volume":"13","author":"Zhu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0945","doi-asserted-by":"crossref","first-page":"1910566","DOI":"10.1002\/adfm.201910566","article-title":"Nanocarrier-mediated cytosolic delivery of biopharmaceuticals","volume":"30","author":"Wei He","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0950","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/ijms22031179","article-title":"Genetic delivery and gene therapy in pulmonary hypertension","volume":"22","author":"Rai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0955","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/hr.2012.217","article-title":"Therapeutic effect of eNOS-transfected endothelial progenitor cells on hemodynamic pulmonary arterial hypertension","volume":"36","author":"Wei","year":"2013","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0960","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00395-009-0065-8","article-title":"Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats","volume":"105","author":"Takemiya","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0965","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-med-041717-085955","article-title":"New and emerging therapies for pulmonary arterial hypertension","volume":"70","author":"Spiekerkoetter","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0970","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10456-021-09797-3","article-title":"Endothelial cell plasticity at the single-cell level","volume":"24","author":"Pasut","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0975","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1134\/S0006297916070063","article-title":"Viral vectors for gene therapy: current state and clinical perspectives","volume":"81","author":"Lukashev","year":"2016","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0980","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2015.05.261","article-title":"Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension","volume":"210","author":"McLendon","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0985","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1161\/CIRCULATIONAHA.118.035889","article-title":"BOLA (BolA family member 3) deficiency controls endothelial metabolism and Glycine homeostasis in pulmonary hypertension","volume":"139","author":"Yu","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb0990","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1598","article-title":"Polymer-mediated gene therapy: recent advances and merging of delivery techniques","volume":"12","author":"Salameh","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2023.11.012_bb0995","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/316214","article-title":"Reducing TRPC1 expression through liposome-mediated siRNA delivery markedly attenuates hypoxia-induced pulmonary arterial hypertension in a murine model","volume":"2014","author":"Sun","year":"2014","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1000","doi-asserted-by":"crossref","first-page":"42544","DOI":"10.1021\/acsami.7b13504","article-title":"ATG101 single-stranded antisense RNA-loaded triangular DNA nanoparticles control human pulmonary endothelial growth via regulation of cell macroautophagy","volume":"9","author":"Du","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.11.012_bb1005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCRESAHA.118.313705","article-title":"CLIC4\/Arf6 pathway","volume":"124","author":"Abdul-Salam","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/cvr\/cvac159","article-title":"BMPR1A promotes ID2-ZEB1 interaction to suppress excessive endothelial to mesenchymal transition","volume":"119","author":"Lee","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4155\/tde-2020-0052","article-title":"Progress in systemic co-delivery of microRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles","volume":"11","author":"He","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCRESAHA.112.267591","article-title":"A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples","volume":"111","author":"Caruso","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/01902148.2014.993776","article-title":"Neuron-derived orphan receptor 1 promoted human pulmonary artery smooth muscle cells proliferation","volume":"41","author":"Wang","year":"2015","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.jconrel.2023.11.012_bb1030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.108.121418","article-title":"Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension","volume":"53","author":"Kimura","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jconrel.2023.11.012_bb1035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCULATIONAHA.121.053980","article-title":"Nanoparticle delivery of STAT3 alleviates pulmonary hypertension in a mouse model of alveolar capillary dysplasia","volume":"144","author":"Sun","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.11.012_bb1040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.biomaterials.2015.07.015","article-title":"Regulation of vascular smooth muscle cell autophagy by DNA nanotube-conjugated mTOR siRNA","volume":"67","author":"You","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.11.012_bb1045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12890-022-01906-2","article-title":"The economic burden of pulmonary arterial hypertension in Spain","volume":"22","author":"Zozaya","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2023.11.012_bb1050","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.121.319971","article-title":"The latest in animal models of pulmonary hypertension and right ventricular failure","volume":"130","author":"Boucherat","year":"2022","journal-title":"Circ. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923007290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:49:35Z","timestamp":1759164575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923007290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":210,"alternative-id":["S0168365923007290"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}